Reports from the Field
New drug reduces diabetic cell decline in type 2 patients
A new study finds that pioglitazone hydrochloride, the most recent addition to the thiazolidinedione class of medications, significantly reduces insulin resistance and reduces the decline of pancreatic cell function in type 2 diabetes patients who receive sulfonylurea therapy, according to data presented at the recent 36th annual European Association for the Study of Diabetes meeting in Jerusalem.
The 16-week, placebo-controlled study of 521 patients found that pioglitazone hydrochloride significantly reduced insulin resistance and improved beta cell function when added to the treatment regimen of patients on sulfonylurea therapy at low (15 mg) and intermediate (30 mg) doses. Adding pioglitazone hydrochloride to sulfonylurea therapy resulted in a 30% reduction in insulin resistance and a 38% improvement in beta cell function compared to baseline.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content